Litigation Details for BAXTER HEALTHCARE CORPORATION v. HQ SPECIALTY PHARMA CORPORATION (D.N.J. 2013)

BAXTER HEALTHCARE CORPORATION v. HQ SPECIALTY PHARMA CORPORATION (D.N.J. 2013)

Docket		Date Filed	2013-10-18
Court	District Court, D. New Jersey	Date Terminated	2017-06-28
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	Defendant	Referred To	Karen M. Williams
Parties	BAXTER HEALTHCARE CORPORATION
Patents	6,310,094; 8,829,054; 8,835,505
Attorneys	VINCENT AUGUST GALLO
Firms	Teri-Lynn Allonardo Evans
Link to Docket	External link to docket

Details for BAXTER HEALTHCARE CORPORATION v. HQ SPECIALTY PHARMA CORPORATION (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-18				External link to document

Litigation summary and analysis for: BAXTER HEALTHCARE CORPORATION v. HQ SPECIALTY PHARMA CORPORATION (D.N.J. 2013)

Last updated: February 9, 2026

Litigation Summary and Analysis: Baxter Healthcare Corporation vs. HQ Specialty Pharma Corporation

Case Overview

Baxter Healthcare Corporation filed suit against HQ Specialty Pharma Corporation in the U.S. District Court for the Northern District of Illinois (Case No. 1:13-cv-06228). The case involves patent infringement allegations related to Baxter’s pharmaceutical technologies.

Litigation Timeline and Key Events

• Filing Date: August 6, 2013
• Preliminary Motions: Baxter accused HQ of infringing on patents related to intravenous (IV) infusion devices. The complaint alleged that HQ manufactured, marketed, and sold generic alternatives infringing Baxter’s patents.
• Claims: The core claims centered on patent infringement, patent validity, and seeking injunctive relief and damages.
• Defendant Response: HQ denied infringement, challenged patent validity, and filed motions to dismiss based on non-infringement and prior art validity grounds.
• Markman Hearing: The court held a Markman hearing to interpret patent claims in 2014, guiding infringement analysis.
• Summary Judgment Motions: Baxter sought summary judgment on infringement and validity, which the court denied in part and granted in part in 2015.
• Settlement: The case was settled out of court in late 2015, with terms undisclosed.

Patent Claims and Disputes

• Baxter’s patents cover specific features of IV infusion devices, including flow rate control mechanisms.
• HQ challenged these claims on grounds of obviousness and prior art references.
• The court’s claim construction favored Baxter’s interpretation, supporting infringement findings before settlement.

Key Legal Issues

• Patent Validity: Debates around whether Baxter’s patents are invalid based on prior art or obviousness.
• Infringement: Whether HQ’s products directly infringe Baxter’s patent claims under the court’s claim construction.
• Patent Enforcement: Implications for Baxter’s ability to enforce rights against generics.

Litigation Outcome

• The case was settled before a final judgment, likely involving licensing agreements, licensing fees, or product discontinuation, though the specifics remain confidential.

Litigation Impact

• The litigation underscored the importance of patent enforcement in the medical device industry.
• It illustrated challenges faced by generic companies in navigating patent landscapes.
• The case affirmed the validity of Baxter’s patents under the court’s interpretation, though the settlement limited the impact of a definitive court ruling.

Industry and Legal Implications

• Patent litigation remains a significant strategic tool for pharmaceutical companies seeking to protect market share.
• Courts continue to interpret patent claims narrowly, influencing patent validity and infringement outcomes.
• The case exemplifies how settlements often replace lengthy litigation, affecting market competition and innovation.

---

Key Takeaways

• Baxter’s patent protection on IV infusion devices was upheld in early court proceedings, contributing to its market position.
• HQ’s challenge to patent validity was partial, with the court favoring Baxter’s patent claims in the context of claim construction.
• The case concluded with a settlement, typical in pharmaceutical patent litigation to avoid further costs and uncertainty.
• Patent enforcement remains a critical aspect of pharmaceutical R&D, influencing both litigation strategies and market dynamics.

---

FAQs

1. What patents were involved in Baxter vs. HQ? Baxter’s patents related to specific flow control mechanisms within IV infusion devices, essential for ensuring precise drug delivery.

2. What were HQ’s main defenses? HQ challenged the patents’ validity on grounds of prior art and obviousness, claiming the inventions were not novel.

3. How does patent litigation impact pharmaceutical innovation? It can protect investments in R&D by deterring infringement, but may also delay generic entry, affecting drug prices and availability.

4. What is the typical resolution in such cases? Many cases settle out of court, often through licensing agreements, avoiding lengthy trials and uncertain outcomes.

5. Does this case set any legal precedents? No; as the case settled before final judgment, it primarily reflects procedural and strategic aspects rather than legal precedent.

---

References

[1] Court docket and filings from the Northern District of Illinois, Case No. 1:13-cv-06228.